Pharvaris N.V. (NASDAQ:PHVS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $49.6364.

PHVS has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research note on Tuesday, June 16th. Morgan Stanley raised their target price on shares of Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Royal Bank Of Canada decreased their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th.

Insider Activity

In other Pharvaris news, insider Peng Lu sold 15,000 shares of Pharvaris stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the completion of the transaction, the insider directly owned 66,083 shares of the company’s stock, valued at $1,998,349.92. The trade was a 18.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Berndt Modig sold 23,333 shares of Pharvaris stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42. Following the transaction, the chief executive officer directly owned 142,084 shares of the company’s stock, valued at approximately $3,941,410.16. This trade represents a 14.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 215,209 shares of company stock valued at $6,431,945. 11.84% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. General Atlantic L.P. boosted its position in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after purchasing an additional 500,000 shares during the period. Foresite Capital Management IV LLC boosted its position in Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after purchasing an additional 368,000 shares during the period. venBio Partners LLC boosted its position in Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. boosted its position in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares during the period. Finally, Commodore Capital LP boosted its position in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares during the period.

Pharvaris Stock Up 2.1%

NASDAQ PHVS opened at $34.01 on Friday. Pharvaris has a 12-month low of $16.72 and a 12-month high of $35.33. The company has a market capitalization of $2.22 billion, a PE ratio of -10.69 and a beta of -2.35. The firm’s 50 day moving average is $30.56 and its 200-day moving average is $27.97.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, sell-side analysts expect that Pharvaris will post -3.22 EPS for the current year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.